Review of rifaximin as treatment for SIBO and IBS

Expert Opinion on Investigational Drugs

Volumn 18, Issue 3, 2009, Pages 349-358

  Pimentel, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Irritable bowel syndrome; Rifaximin; Small intestinal bacterial overgrowth

Indexed keywords

LEVOFLOXACIN; METRONIDAZOLE; MIDAZOLAM; RIFAXIMIN; RIFAMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL FLORA; BACTERIAL OVERGROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HUMAN; IRRITABLE COLON; PHARMACODYNAMICS; REVIEW; SMALL INTESTINAL BACTERIAL OVERGROWTH; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG TOLERANCE; ENTEROPATHY; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG TOLERANCE; HUMANS; INTESTINAL DISEASES; MICROBIAL VIABILITY; RIFAMYCINS;

EID: 67449083400     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902780175     Document Type: Review

References (47)

1. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005;34:189-204 (Pubitemid 40615950)
2. Malagelada JR. A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation. Int J Clin Pract 2006;60:57-63 (Pubitemid 43732577)
3. Hungin APS, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-75 • This article is the result of a two-phase community survey and is an in-depth analysis of the status of IBS in the US.
4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-1511 (Pubitemid 34465190)
5. Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(Suppl 2):1-9 • This is a description of the varied mechanisms contributing to and interacting in this complex disease state and it gives a basis for why IBS may be so difficult to identify and treat.
6. Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am 2005;34:319-35 •• This work further expands the complexity of treating IBS by describing the many classes of therapies needed to treat multiple symptoms, as well as reviewing the evidence demonstrating efficacy. It also updates the American College of Gastroenterology's comprehensive review of IBS therapies from 2002.
7. Lotronex [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006
8. FDA public health advisory: tegaserod maleate (marketed as Zelnorm). Food and Drug Administration. Available from: http://www.fda.gov/cder/drug/advisory/ tegaserod.htm [Last accessed 10 November 2008]
9. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852-8 •• This article provides the framework for understanding how SIBO may be a unifying explanation for many of the symptoms related to IBS. (Pubitemid 39079672)
10. Galatola G, Grosso M, Barlotta A, et al. Diagnosis of bacterial contamination of the small intestine using the 1g [14C] xylose breath test in various gastrointestinal diseases. Minerva Gastroenterol Dietol 1999;37:169-175
11. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6 • This article is the first double-blind study to investigate antibiotics in IBS.
12. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-9 •• This study establishes the presence of abnormal lactulose breath test as common in patients with IBS and employs the test following antibiotic therapy to verify improvement in symptoms with eradication of overgrowth.
13. Nucera G, Lupascu A, Gabrielli M, et al. Sugar intolerance in irritable bowel syndrome: the role of small bowel bacterial overgrowth [DDW abstract T1783]. Gastroenterology 2004;126 (4 suppl 2):A-511
14. Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157-1160 (Pubitemid 41779524)
15. McCallum R, Schultz C, Sostarich S. Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT) [DDW abstract T1118]. Gastroenterology 2005;128 (4 suppl 2):A-460
16. Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;21:1391-5 • This study demonstrates that a majority of patients with IBS have underlying SIBO and that eradication of the overgrowth is associated with a reduction of symptoms in a substantial number of those patients.
17. 14C-D-xylose and healthy controls. Am J Gastroenterol 2005;100:1566-1570
18. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006;52:89-95 (Pubitemid 43672299)
19. Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007;13:6016-6021 (Pubitemid 350238268)
20. Madrid AM, Defilippi CC, Defillipi GC, et al. Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases. Rev Med Chil 2007;135:1245-1252
21. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007;52:139-142
22. Carrara M, Desideri S, Azzurro M, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2008;12:197-202
23. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008;103:958-963
24. Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil 2008;20 (9):998-1008
25. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73 (suppl 1):13-27 •• This review establishes the attributes of rifaximin as a gastrointestinal selective antibiotic and discusses the role of gastrointestinal bacteria in several gastrointestinal diseases. (Pubitemid 43296214)
26. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005;5:19-30 •• This article reviews studies that establish the efficacy of rifaximin in treating travelers' diarrhea and discusses how its pharmacokinetics may contribute to potential uses in treating other gastrointestinal disorders.
27. Xifaxan [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2008 •• Prescribing information for rifaximin.
28. DuPont HL. New antibacterial agents in the management of acute infectious diarrhea. Clin Update Infect Dis 2004;7:1-4. Available from: http://www.nfid.org/pdf/id-archive/acutediarrhea.pdf [Last accessed 10 November 2008 ] • This paper discusses management tactics in utilizing antibacterial agents in the treatment of infectious diarrhea.
29. Taylor DN, McKenzie R, Durbin A, et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 2008;52:1179-81 •• This paper evaluates pharmacokinetic parameters of rifaximin in patients with travelers' diarrhea and supports the minimal serum levels previously demonstrated in healthy volunteers.
30. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-56 (Pubitemid 24289441)
31. Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacother 2007;27:1361-9 •• This study evaluates the potential of rifaximin to inhibit or induce P450 (CYP) enzymes, and the findings support the absence of drug interaction of rifaximin with substrates of intestinal and/or hepatic CYP3A enzymes. (Pubitemid 47530442)
32. Trapnell CB, Connolly M, Pentikis H, et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007;41:222-228 (Pubitemid 46340052)
33. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-2206
34. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-5 • This study establishes the optimal dose for rifaximin in the treatment of SIBO.
35. Lauritano EC, Lupascu A, Scarpellini E, et al. A dose-finding study of rifaximin in the treatment of small bowel bacterial overgrowth in patients with irritable bowel syndrome [DDW abstract M1174]. Gastroenterology 2006;130(4 suppl 2):A-317
36. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007;25:781-786 (Pubitemid 46434913)
37. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-63 •• This study demonstrated that over a 10-week period, rifaximin treatment resulted in greater improvement of IBS symptoms and resulted in a lower bloating score versus placebo. (Pubitemid 46780934)
38. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33 •• This study supports the conclusion that rifaximin is a safe and effective treatment for abdominal bloating and flatulence associated with IBS; symptom improvement correlated with reduction in H2-breath excretion.
39. Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53:169-74 •• This study demonstrates that rifaximin is more effective than other antibiotics in improving IBS symptoms among patients with abnormal lactulose breath test, even when a patient fails to respond to a previous antibiotic.
40. Lembo A, Zakko S, Ferreira N, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response [DDW abstract T1390]. Gastroenterology 2008;134:A-545 •• This study demonstrates the efficacy of rifaximin as well as sustained results throughout 12 weeks of follow-up.
41. Ringel Y, Zakko S, Ferreira N, et al. Predictors of clinical response from a phase 2 multi-center efficacy trial using rifaximin, a gut-selective, nonabsorbed antibiotic for the treatment of diarrhea-associated irritable bowel syndrome [DDW abstract T1411]. Gastroenterology 2008;134:A-550
42. Baidoo L, Kundu R, Berenbaum PL, et al. Rifaximin is effective therapy for small bowel bacterial overgrowth [DDW abstract W1732]. Gastroenterology 2005;128(4 suppl 2):A-672
43. Majewski M, Sostarich S, Foran P, McCallum RW. Is rifaximin effective treatment for small intestinal bacterial overgrowth? [ACG abstract 293]. Am J Gastroenterol 2006;101 (suppl):S141
44. Lupascu A, Lauritano C, Gabrielli M, et al. Antibiotic treatment in small bowel bacterial overgrowth in patients with irritable bowel [DDW abstract 1741]. Gastroenterology 2005;128 (suppl 2):A-674 (Pubitemid 41779524)
45. Gabrielli M, Lauritano C, Scarpellini E, et al. Rifaximin versus systemic antibiotics for the treatment of small bowel bacterial overgrowth [DDW abstract S1165]. Gastroenterology 2007;132 (4 suppl 2):A-187 •• This study compares rifaximin to systemic antibiotics (metronidazole and levofloxacin) for efficacy, safety and tolerability in the treatment of SIBO. It finds that while rifaximin has similar efficacy compared with systemic antibiotics, it has significantly improved tolerability.
46. Rifaximin 3 times/day for non-constipation IBS (TARGET 2). Available from: http://clinicaltrials.gov/ct2/show/NCT00724126?term=rifaximin&rank=6 [Last accessed 10 November 2008 ]
47. Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther 2006;4:417-427 (Pubitemid 43905464)